- Market Capitalization, $K 3,193,609
- Shares Outstanding, K 157,787
- Annual Sales, $ 1,171 M
- Annual Income, $ -196,620 K
- 60-Month Beta 1.97
- Price/Sales 2.75
- Price/Cash Flow 35.13
- Price/Book 2.96
|Period||Period Low||Period High||Performance|
| || |
+1.72 (+9.26%)since 01/21/20
| || |
+0.16 (+0.80%)since 11/21/19
| || |
-12.33 (-37.86%)since 02/21/19
We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...
Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $18.70 to a high of $19.75. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $18.82...
Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26, 2020 at 9:00 a.m. ET (2:00 p.m. GMT)...
Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.
Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $17.93 to a high of $19.97. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $18.80...
Alkermes beats earnings and sales estimates in the fourth quarter of 2019.
DUBLIN (AP) _ Alkermes PLC (ALKS) on Thursday reported a loss of $5.4 million in its fourth quarter.
Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.